Winnipeg, Canada

Time filter

Source Type

News Article | December 16, 2016
Site: www.marketwired.com

WINNIPEG, MANITOBA--(Marketwired - Dec. 16, 2016) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Corporation" or "Kane Biotech") today announced that a special resolution of the shareholders of the Corporation was passed at the special meeting of shareholders of the Corporation held on December 16, 2016 approving the consolidation of the common shares of the Corporation (the "Common Shares") on a five to one basis (the "Consolidation").The Corporation currently has 227,390,037 Common Shares issued and outstanding. Following the implementation of the Consolidation by the Corporation, the Corporation anticipates that it will have approximately 45,478,007 Common Shares issued and outstanding. The board of directors of the Corporation has not yet determined when it will proceed to implement the Consolidation. The number of Common Shares reserved for issuance under the Corporation's stock option plan and the number of Common Shares that may be purchased upon exercise of other convertible securities of the Corporation will be reduced proportionately. Further details with respect to the Consolidation are contained in the Corporation's management information circular dated November 14, 2016, a copy of which is available on SEDAR at www.sedar.com. The completion of the Consolidation remains subject to the final approval of the TSX Venture Exchange. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, and foodborne bacterial infections. According to the United States National Institutes of Health biofilms are estimated to be responsible for 80% of all human bacterial infections and cost individuals, industry, governments and hospitals billions of dollars each year. As such, there is significant interest in safe and effective products that can combat the biofilm problem. Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Corporation has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications. Kane Biotech has a portfolio of biotechnologies, intellectual property (patents, patents pending and trademarks) and products developed by the Corporation's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE". The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: the Corporation's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in the Corporation's filings with Canadian securities regulatory authorities, as well as the Corporation's ability to anticipate and manage the risks associated with the foregoing. The Corporation cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on the Corporation's forward-looking statements to make decisions with respect to the Corporation's, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Corporation cannot provide assurance that actual results will be consistent with these forward-looking statements. The Corporation undertakes no obligation to update or revise any forward-looking statement.


News Article | November 25, 2016
Site: www.marketwired.com

WINNIPEG, MANITOBA--(Marketwired - Nov. 25, 2016) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Corporation" or "Kane Biotech") today announced that the Corporation has sent a notice of meeting, management information circular, proxy and related materials (the "Meeting Materials") to its shareholders in connection with a special meeting of shareholders (the "Meeting") to be held on December 16, 2016 at 2:00 pm (Winnipeg time). At the Meeting, shareholders of the Corporation will be asked to approve a resolution approving the consolidation of the common shares of the Corporation (the "Common Shares") on a five to one basis (the "Consolidation"). The Corporation currently has 227,390,037 Common Shares issued and outstanding. If the Consolidation is approved by shareholders and implemented by the Corporation, following the Consolidation the Corporation will have approximately 45,478,007 Common Shares issued and outstanding. The number of Common Shares reserved for issuance under the Corporation's stock option plan and the number of Common Shares that may be purchased upon exercise of other convertible securities of the Corporation will be reduced proportionately. Further details with respect to the Consolidation are contained in the Corporation's management information circular dated November 14, 2016, a copy of which is available on SEDAR at www.sedar.com. The Corporation is undertaking the Consolidation in order to comply with the policies of the TSX Venture Exchange (the "Exchange"). On June 29, 2016, the Corporation completed a private placement offering of its Common Shares at a price of $0.03 per Common Share. Due to the fact that Common Shares were issued at a price lower than $0.05 per Common Share, the Corporation was required to obtain a waiver from the Exchange to proceed with the private placement. In order to obtain the waiver from the Exchange, the Corporation agreed to seek the approval of its shareholders for the Consolidation within six months of the closing of the private placement. The completion of the Consolidation remains subject to the final approval of the Exchange. The Corporation will not be changing its name or completing any other restructuring in connection with the Consolidation. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, and foodborne bacterial infections. According to the United States National Institutes of Health biofilms are estimated to be responsible for 80% of all human bacterial infections and cost individuals, industry, governments and hospitals billions of dollars each year. As such, there is significant interest in safe and effective products that can combat the biofilm problem. Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Corporation has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications. Kane Biotech has a portfolio of biotechnologies, intellectual property (patents, patents pending and trademarks) and products developed by the Corporation's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE". The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: the Corporation's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in the Corporation's filings with Canadian securities regulatory authorities, as well as the Corporation's ability to anticipate and manage the risks associated with the foregoing. The Corporation cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on the Corporation's forward-looking statements to make decisions with respect to the Corporation's, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Corporation cannot provide assurance that actual results will be consistent with these forward-looking statements. The Corporation undertakes no obligation to update or revise any forward-looking statement.


News Article | December 21, 2016
Site: www.marketwired.com

WINNIPEG, MANITOBA--(Marketwired - Dec. 21, 2016) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Corporation") announced that on December 21, 2016, it issued 251,385 common shares of the Corporation ("Common Shares") in payment of $12,569 in interest owing on the Corporation's $500,000 2 year 10% convertible redeemable unsecured note (the "Note") as at December 18, 2016. Pursuant to the terms of the Note, the Corporation has the option to issue Common Shares in lieu of cash in payment of interest on the Note at a deemed price per share equal to the market price of the Common Shares on the applicable interest payment date, subject to a minimum price of $.05 per share and the approval of the TSX Venture Exchange (the "Exchange"). The approval of the Exchange for the issuance of the Common Shares was obtained by the Corporation on December 21, 2016. The Common Shares issued by the Corporation are restricted from transfer for a period of four months from the date of issuance in accordance with applicable securities laws and TSX Venture Exchange policies. The holder of the Note is Philip Renaud, a director and the Chairman of the Corporation. As Mr. Renaud is a director and Chairman of the Corporation, the issuance of the Common Shares to Mr. Renaud in payment of interest owing to him is considered to be a "related party transaction" for the purposes of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). In accordance with MI 61-101, the Corporation is not required to obtain a formal valuation or minority approval of the transaction due to the fact that it may rely on an exemption to those requirements contained in MI 61-101, namely that the fair market value of the transaction is not more than 25% of the market capitalization of the Corporation. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, and foodborne bacterial infections. According to the United States National Institutes of Health biofilms are estimated to be responsible for 80% of all human bacterial infections and cost individuals, industry, governments and hospitals billions of dollars each year. As such, there is significant interest in safe and effective products that can combat the biofilm problem. Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Corporation has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications. Kane Biotech has a portfolio of biotechnologies, intellectual property (patents, patents pending and trademarks) and products developed by the Corporation's own biofilm research expertise and acquired from leading research institutions. Strix NB®, StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE". The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.


The present invention provides compositions comprising an antibiofilm enzyme, a soluble -N-acetylglucosaminidase similar to the dspB gene (DispersinB), and an antimicrobial for preventing growth and proliferation of biofilm-embedded microorganisms in acute and chronic wounds, and methods of treatment. The invention further provides methods for preparing medical devices, and in particular, wound care devices using soluble -N-acetylglucosaminidase based antimicrobial compositions.


Patent
Kane Biotech | Date: 2010-01-22

The present invention provides novel compositions comprising: (a) protamine sulfate and (b) benzalkonium chloride or a silver containing particle; or (a) sodium metaperiodate and (b) 5-fluorouracil or chlorhexidine and uses thereof for the preparation of devices, and in particular medical devices, susceptible to colonization by biofilm forming bacteria.


Patent
Kane Biotech | Date: 2014-05-01

The present invention provides novel compositions comprising: (a) a metaperiodate and (b) chlorhexidine or a chlorohexidine salt and uses thereof for the preparation of devices, and in particular medical devices, susceptible to colonization by biofilm forming bacteria.


Compositions comprising chelating agents, metal ion salts, gelling agents or a buffer, antimicrobials, antibiofilm agents and a pH adjuster or a buffer for the prevention and treatment of wound infections and food-borne diseases involving bacterial biofilms are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive wound infection associated bacteria occurring in polymicrobial biofilms. The composition may be in the form of lotion, cream, ointment, dressing, bandage, rinse, soak, gel, spray, or other suitable forms, including certain devices. Additionally, the invention offers an efficient method of delivering the formulated composition containing one or two chelating agents or chelating agents alone or in combination with a metal ion salt using either a nanoparticle or other efficient delivery systems.


Patent
Kane Biotech | Date: 2010-05-12

The present invention includes compositions for preventing growth and proliferation of biofilm embedded microorganisms comprising: (a) a cationic polypeptide and (b) a bis-gaunide or a salt thereof. The invention further provides methods for preparing objects with such compositions, and objects and consumables (such as household cleaners) comprising such compositions.


Trademark
Kane Biotech | Date: 2015-11-17

Oral care water additive for pets; oral care spray for pets; oral care products for pet, animal and human uses, namely, water additives, foams, toothpaste, powder additives for water and food, rawhides, wipes, breath mints, tablets, pills, liquid sachets, gels. Wound care products for pet and human uses, namely, shampoos, otic drops, wound sprays, wound gel, bandages, wipes, lotions, creams, wound treatment products for pet and human uses; nutritional care products, namely, natural health products for pets and humans, pill supplements for pet and human uses; food additives; animal feed; pet food, dog food and cat food; pet treats, pet biscuits and pet chewables. Manufacturing and distribution of (i) oral care products for pet, animal and human uses, namely, water additives, oral care spray for pets, foams, toothpaste, powder additives for water and food, rawhides, wipes, breath mints, tablets, pills, liquid sachets, gels; (ii) pet food, pet biscuits, pet treats, dog food, cat food, pet chewables; (iii) animal feed; (iv) wound care products for pet and human uses, namely, shampoos, otic drops, wound sprays, wound gel, bandages, wipes, lotions, creams, wound treatment products for pet and human uses; (v) nutritional care products, namely, natural health products for pets and humans, pill supplements for pet and human uses; (vi) food additives; (vii) oral care water additive for pets; Wholesale and retail services of (i) oral care products for pet, animal and human uses, namely, water additives, oral care spray for pets, foams, toothpaste, powder additives for water and food, rawhides, wipes, breath mints, pills, tablets, liquid sachets, gels; (ii) pet food, pet biscuits, pet treats, dog food, cat food, pet chewables; (iii) animal feed; (iv) wound care products for pet and human uses, namely, shampoos, otic drops, wound sprays, wound gel, bandages, wipes, lotions, creams, wound treatment products for pet and human uses; (v) nutritional care products, namely, natural health products for pets and humans, pill supplements for pet and human uses; (vi) food additives; oral care water additive for pets; Online retail store services in the field of (i) oral care water additive for pets; (ii) oral care spray for pets; (iii) oral care products for pet, animal and human uses, namely, water additives, foams, toothpaste, powder additives for water and food, rawhides, wipes, breath mints, tablets, pills, liquid sachets, gels; (iv) pet food, pet biscuits, pet treats, dog food, cat food, pet chewables; (v) animal feed; (vi) wound care products for pet and human uses, namely, shampoos, otic drops, wound sprays, wound gel, bandages, wipes, lotions, creams, wound treatment products for pet and human uses; (vii) nutritional care products, namely, natural health products for pets and humans, pill supplements for pet and human uses; (viii) food additives; Operation and maintenance of an internet website containing information on the subject of (i) oral care products for pet, animal and human uses, namely, water additives, oral care spray for pets, foams, toothpaste, powder additives for water and food, rawhides, wipes, breath mints, tablets, pills, liquid sachets, gels; (ii) pet food, pet biscuits, pet treats, dog food, cat food, pet chewables; (iii) animal feed; (iv) wound care products for pet and human uses, namely, shampoos, otic drops, wound sprays, wound gel, bandages, wipes, lotions, creams, wound treatment products for pet and human uses; (v) nutritional care products, namely, natural health products for pets and humans, pill supplements for pet and human uses; (vi) food additives; (vii) oral care water additive for pets.


Loading Kane Biotech collaborators
Loading Kane Biotech collaborators